BNP Paribas’s Vertex Pharmaceuticals VRTX Stock Holding History

BNP Paribas’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.99M	Sell	4,002 -289	-7%	-$128K	0.05%	141
2026 Q1	$1.92M	Sell	4,291 -2,848	-40%	-$1.33M	0.06%	145
2025 Q4	$3.24M	Buy	7,139 +1,798	+34%	+$775K	0.09%	115
2025 Q3	$2.09M	Sell	5,341 -235	-4%	-$98.2K	0.06%	124
2025 Q2	$2.48M	Sell	5,576 -258	-4%	-$119K	0.08%	120
2025 Q1	$2.83M	Sell	5,834 -350	-6%	-$163K	0.12%	107
2024 Q4	$2.49M	Buy	6,184 +531	+9%	+$246K	0.01%	109
2024 Q3	$2.63M	Sell	5,653 -282	-5%	-$135K	0.11%	91
2024 Q2	$2.78M	Sell	5,935 -1,160	-16%	-$503K	0.14%	87
2024 Q1	$2.97M	Buy	+7,095	New	+$3M	0.14%	88

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BNP Paribas's VRTX Position: Q2 2026 in Review

BNP Paribas reduced its Vertex Pharmaceuticals (VRTX) stake by 6.7% in Q2 2026, selling an estimated $128K and leaving 4,002 shares worth $1.99M. The position accounts for 0.05% of the portfolio, ranked #141.

BNP Paribas first reported a position in VRTX in Q1 2024 and has held it in 10 quarters since. The position peaked at $3.24M in Q4 2025. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

BNP Paribas held 4,002 shares of Vertex Pharmaceuticals worth $1.99M as of Q2 2026.
BNP Paribas sold 289 Vertex Pharmaceuticals shares in Q2 2026, an estimated $128K.
Vertex Pharmaceuticals made up 0.05% of BNP Paribas's portfolio in Q2 2026, its #141 holding.
BNP Paribas first reported a position in Vertex Pharmaceuticals in Q1 2024 and has held it in 10 quarters since.
BNP Paribas's Vertex Pharmaceuticals position peaked at $3.24M in Q4 2025.
1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on BNP Paribas's 13F filing for Q2 2026, filed 13 Aug 2026.